Lakefront Biotherapeutics (GLPGF) Interest Coverage Ratio Growth (1y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Interest Coverage Ratio Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 176.09% |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 128.53% |
| Dec 31, 2025 | -519.60% |
| Sep 30, 2025 | 53.28% |
| Jun 30, 2025 | -76.72% |
| Mar 31, 2025 | 55.99% |
| Dec 31, 2024 | 48.66% |
| Mar 31, 2024 | 675.38% |
| Dec 31, 2023 | -20,367.83% |
| Mar 31, 2023 | 234.60% |
| Mar 31, 2022 | 12.28% |
| Mar 31, 2021 | 141.06% |
| Jun 30, 2020 | 20.34% |
| Mar 31, 2020 | -91.82% |
| Dec 31, 2019 | 119.25% |
| Sep 30, 2019 | 61.28% |
| Jun 30, 2019 | 595.91% |
| Mar 31, 2019 | 381.50% |
| Dec 31, 2018 | 37.13% |
| Sep 30, 2018 | -829.51% |
| Jun 30, 2018 | -528.97% |